Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER StudyMENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study. PATHFINDER 2 was initiated in 2021 to evaluate the safety and ...

Core Viewpoint - Quest Diagnostics has announced a collaboration with The University of Texas MD Anderson Cancer Center to develop a blood test aimed at improving cancer risk assessment and screening for individuals at elevated risk [1][2]. Group 1: Collaboration and Test Development - Quest Diagnostics will develop and validate a laboratory-developed blood test based on circulating protein biomarkers linked to high cancer risk, including cancers such as colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal, and stomach [2]. - The test will utilize technology and intellectual property from the Multi-Cancer Stratification Test (MCaST), developed by Dr. Samir Hanash and his team at MD Anderson, which is based on extensive clinical research involving tens of thousands of individuals [2]. - If the test validation is successful, Quest may commercialize the test, aiming for availability to providers in North America by 2026 [3]. Group 2: Test Purpose and Market Need - The future test is intended to supplement conventional screening methods by providing insights that help identify patients who would benefit from appropriate cancer screenings, addressing the limitations of current methods that often target a limited number of cancers [4]. - Current screening methods can be invasive, inconvenient, or costly, leading to a significant number of patients skipping preventive screenings; only 51% of U.S. adults reported having a routine medical appointment or cancer screening in the last year [5][6]. - Quest aims to create a simple and affordable blood test to identify risks for various cancers, potentially encouraging patients to pursue preventive screenings and early medical assessments [6].

GRAIL (GRAL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants None - ExecutiveBob Ragusa - CEO & Board MemberHarpal Kumar - President Biopharma Business & EuropeJoshua Ofman - PresidentAaron Freidin - Chief Financial OfficerSubbu Nambi - Managing DirectorDoug Schenkel - Managing Director Conference Call Participants Tejas Savant - Executive Director & Senior Healthcare Equity AnalystKyle Mikson - Managing Director & Senior Research Analyst Operator Good day, ladies and gentlemen, and welc ...

GRAIL (GRAL) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, ladies and gentlemen, and welcome to the GRAIL First Quarter twenty twenty five Earnings Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that this conference call is being recorded. Grail Investor Relations, please begin. Speaker1 Thanks, operator, and thanks, everyone, for joining us today. On today's call are Bob Bergu ...

Core Insights - GRAIL, Inc. has announced a partnership with athenahealth to integrate its Galleri multi-cancer early detection test into athenahealth's EHR solution, athenaOne, enhancing the ordering process for clinicians [1][2][3] Company Overview - GRAIL is focused on early cancer detection using advanced technologies such as next-generation sequencing and machine learning, aiming to alleviate the global burden of cancer [4] - The Galleri test identifies DNA shed by cancer cells through a simple blood draw, allowing for the detection of multiple deadly cancers before symptoms appear [6] Partnership Details - The integration with athenaCoordinator Core will enable over 160,000 U.S. clinicians to order the Galleri test directly within their EHR, streamlining the process and reducing administrative burdens [2][3] - The Galleri test results will be automatically available in the patient chart, further simplifying the workflow for healthcare providers [2] Test Specifications - The Galleri test is recommended for adults aged 50 or older with an elevated risk for cancer and should be used alongside standard cancer screenings [6][9] - The test can indicate the origin of cancer, providing healthcare providers with valuable information for further investigation [6] Sensitivity Data - The sensitivity of the Galleri test varies by cancer type, with pancreas cancer showing 83.7% sensitivity overall, and liver/bile duct cancer at 93.5% [8]